as 11-15-2024 4:00pm EST
Stocks
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Founded: | 2004 | Country: | Cayman Islands |
Employees: | 127 | City: | N/A |
Market Cap: | 115.1M | IPO Year: | 2023 |
Target Price: | $9.00 | AVG Volume (30 days): | 29.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.32 | EPS Growth: | N/A |
52 Week Low/High: | $1.85 - $17.48 | Next Earning Date: | 08-08-2024 |
Revenue: | $5,000,000 | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
ANL Breaking Stock News: Dive into ANL Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 months ago
GlobeNewswire
3 months ago
GlobeNewswire
3 months ago
The Telegraph
5 months ago
Simply Wall St.
5 months ago
Simply Wall St.
5 months ago
Simply Wall St.
5 months ago
Motley Fool
5 months ago
The information presented on this page, "ANL Adlai Nortye Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.